In this pilot assessment of MAP4K4 inhibition in 5 primary human gliomas, we found three tumor cell populations demonstrated a significant reduction of cell migration speed, one with no significant change, and one with a nominal significant enhanced migration with pharmacologic inhibition of MAP4K4. The gene discussed is MAP4K4; the disease is central nervous system cancer.